Fig. 4From: Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trialsRisk of gallbladder or biliary diseases in DPP4i compared with placebo. Gallbladder or biliary diseases include cholecystitis, cholangitis, cholelithiasis, bile duct stone and biliary colicBack to article page